ETNB - 89bio completes enrollment in BIO89-100 NASH study

89bio (NASDAQ:ETNB) announces that it has completed target enrollment of 20 patients in the paired-biopsy, open-label histology cohort in biopsy-confirmed fibrosis stage F2 – F3 NASH patients. The key efficacy endpoints include a 2-point or greater improvement in the NAFLD Activity Score (NAS), NASH resolution without worsening of fibrosis, and the improvement of fibrosis ? 1 stage without worsening of the condition. The company said that it expects to post topline results from the study by year-end 2021.

For further details see:

89bio completes enrollment in BIO89-100 NASH study